Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News BG Medicine Inc BGMD

Metals & Mining Technology Industrial Metals & Minerals Scientific & Technical Instruments

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in... see more

Add To Watchlist

Recent & Breaking News (GREY:BGMD)

Wall Street Rallies Again as Russia Outmaneuvers Washington

Equities.com March 18, 2014

BG Medicine (BGMD) Leaps on Potential Short Squeeze

Equities.com March 18, 2014

BG Medicine Announces Fiscal Year 2013 Financial Results Release Date and Conference Call Information

GlobeNewswire March 13, 2014

BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease

GlobeNewswire March 12, 2014

BG Medicine Compliant With NASDAQ Listing Requirements

GlobeNewswire March 11, 2014

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

GlobeNewswire March 10, 2014

Five Star Equities Issues New Research Reports on BGMD, ELON, KRA and LTRX

Accesswire January 30, 2014

Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study

Globe Newswire January 28, 2014

BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension

Globe Newswire January 27, 2014

TrendingWallStreet.com Releases Trend Reports on DM, CHTP, BZNE, and BGMD

Accesswire January 6, 2014

TrendingWallStreet.com Begins Trend Analysis on TGRO, VMEM, GLSO, and BGMD

Accesswire December 13, 2013

Five Star Equities Issues New Research Reports on AVNR, BGMD, CYTR and ECTE

Accesswire December 12, 2013

TrendingWallStreet.com Initiates Volume Coverage on AU, NNRX, BGMD, and PLUG

Accesswire December 11, 2013

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

Globe Newswire December 10, 2013

Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure

Globe Newswire November 19, 2013

BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer

Globe Newswire November 14, 2013

AXAS, POZN, ATRS and BGMD added to NASDAQ Active Stock Watch List at EPR

Accesswire November 6, 2013

BG Medicine Reports 2013 Third Quarter Financial Results

Globe Newswire November 6, 2013

SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test

Globe Newswire November 6, 2013

BG Medicine to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, November 6, 2013

Globe Newswire October 30, 2013